DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapyECCO '18 Vienna
2018
DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitisECCO '18 Vienna
2018
DOP064: ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel diseaseECCO '18 Vienna
2018
DOP065: Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trialECCO '18 Vienna
2018
DOP068: Crohn’s disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trialECCO '18 Vienna
2018
DOP069: Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trialECCO '18 Vienna
2018
DOP070: Development and pilot of an index to identify young people with inflammatory bowel disease at risk of psychological morbidityECCO '18 Vienna
2018
DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohortECCO '18 Vienna
2018
DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repairECCO '18 Vienna
2018
DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel diseaseECCO '18 Vienna
2018
DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitisECCO '18 Vienna
2018
DOP077: Deep immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s diseaseECCO '18 Vienna
2018
DOP078: Visceral and subcutaneous adipose tissues of Crohn’s disease patients contains bacteriaECCO '18 Vienna
2018
DOP079: Heat-shock protein GP96 is essential for self-renewal of the intestinal epithelial barrierECCO '18 Vienna
2018